[go: up one dir, main page]

MX2022003190A - Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. - Google Patents

Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.

Info

Publication number
MX2022003190A
MX2022003190A MX2022003190A MX2022003190A MX2022003190A MX 2022003190 A MX2022003190 A MX 2022003190A MX 2022003190 A MX2022003190 A MX 2022003190A MX 2022003190 A MX2022003190 A MX 2022003190A MX 2022003190 A MX2022003190 A MX 2022003190A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
bacteriochlorophyll derivative
bchl
agent
Prior art date
Application number
MX2022003190A
Other languages
English (en)
Inventor
Avigdor Scherz
Yoram Salomon
Liiach Agemy
Rachel Hamri
Dina Preise
Kwanghee Kim
Jonathan Coleman
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2022003190A publication Critical patent/MX2022003190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un agente anti-células supresoras derivadas del linaje mieloide ("agente anti-MDSC") y un derivado de bacterioclorofila (de aquí en lo sucesivo en la presente solicitud "Bchl-D) para ser utilizados en terapia de combinación para cáncer, en donde el agente anti-MDSC y el Bchl-D se administran en forma secuencial y la administración de Bchl-D es seguida por terapia fotodinámica (PDT) o PDT dirigida vascular (VTP).
MX2022003190A 2016-04-10 2018-10-10 Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. MX2022003190A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10

Publications (1)

Publication Number Publication Date
MX2022003190A true MX2022003190A (es) 2022-04-11

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012392A MX390751B (es) 2016-04-10 2017-04-10 Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2022003190A MX2022003190A (es) 2016-04-10 2018-10-10 Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018012392A MX390751B (es) 2016-04-10 2017-04-10 Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.

Country Status (14)

Country Link
US (2) US11278555B2 (es)
EP (1) EP3442582A1 (es)
JP (2) JP2019510807A (es)
KR (2) KR20190008206A (es)
CN (2) CN109862918A (es)
AU (2) AU2017250732B2 (es)
BR (1) BR112018070847A2 (es)
CA (1) CA3020067A1 (es)
IL (1) IL262191B2 (es)
MX (2) MX390751B (es)
RU (2) RU2021110230A (es)
SG (1) SG11201808849TA (es)
WO (1) WO2017179053A1 (es)
ZA (1) ZA201807187B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
KR102224028B1 (ko) 2014-05-30 2021-03-05 데이코 아이피 홀딩스 엘엘시 방출기, 공압식 제어 밸브 및 선택적인 흡인기를 갖는 진공 생성 시스템
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
KR20220100546A (ko) * 2021-01-08 2022-07-15 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1137411E (pt) 1998-12-09 2007-02-28 Yeda Res & Dev Processo para inibir respostas ao etileno em plantas
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) * 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
JP2010502574A (ja) * 2006-08-23 2010-01-28 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｒｇｄペプチドとポルフィリン又は（バクテリオ）クロロフィル光合成剤とのコンジュゲート及びその使用
BRPI0920108A2 (pt) 2008-10-23 2016-12-13 Steba Biotech N V peptídomimético cíclico contendo argina, glicina, ácido aspártico (rgd), conjugado de peptidomimético cíclico contendo rgd, composição farmacêutica, conjugado e uso do mesmo.
CA2825599C (en) 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
ZA201807187B (en) 2020-01-29
KR20220139445A (ko) 2022-10-14
CN109862918A (zh) 2019-06-07
AU2017250732B2 (en) 2022-11-10
IL262191B2 (en) 2025-01-01
WO2017179053A1 (en) 2017-10-19
JP2022031823A (ja) 2022-02-22
US20190125769A1 (en) 2019-05-02
AU2023200591A1 (en) 2023-03-09
AU2017250732A1 (en) 2018-11-15
IL262191A (en) 2018-11-29
RU2018139523A3 (es) 2020-07-07
EP3442582A1 (en) 2019-02-20
IL262191B1 (en) 2024-09-01
RU2747258C2 (ru) 2021-04-29
CA3020067A1 (en) 2017-10-19
KR20190008206A (ko) 2019-01-23
RU2021110230A (ru) 2021-05-26
US11278555B2 (en) 2022-03-22
US20220202838A1 (en) 2022-06-30
RU2018139523A (ru) 2020-05-15
JP2019510807A (ja) 2019-04-18
SG11201808849TA (en) 2018-11-29
MX2018012392A (es) 2019-08-21
CN118304400A (zh) 2024-07-09
MX390751B (es) 2025-03-21
BR112018070847A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
EP4603098A3 (en) Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
WO2016025635A3 (en) Combination therapy for treating cancer
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
SG10201902664RA (en) Combination therapy for treating cancer
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2016043874A3 (en) Combination therapy for treating cancer
MX2020009773A (es) Terapia de combinacion.
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020001727A (es) Terapia de combinacion.
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
MX2019013862A (es) Terapia de combinacion.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MX2018004112A (es) Terapia de combinacion racional para el tratamiento de cancer.
PH12018501790A1 (en) Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2019003751A (es) Proteina terapeutica.